You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

 

Online download statistics by month:

Online download statistics by month: March 2021 to January 2026

AbstractFullPdf
Mar 2021383384139
Apr 2021260260131
May 202139739758
Jun 2021159159102
Jul 202112112166
Aug 202114214242
Sep 2021939352
Oct 2021878757
Nov 2021999855
Dec 2021909035
Jan 2022889351
Feb 2022656745
Mar 2022555530
Apr 202210210556
May 20229910065
Jun 2022768039
Jul 2022586441
Aug 2022757536
Sep 2022535433
Oct 2022787943
Nov 2022636743
Dec 2022585825
Jan 2023434322
Feb 2023818132
Mar 2023555651
Apr 2023333348
May 2023414124
Jun 2023363621
Jul 2023383826
Aug 2023474729
Sep 2023555528
Oct 2023626228
Nov 2023474721
Dec 2023555546
Jan 2024444530
Feb 2024525228
Mar 2024474794
Apr 2024424243
May 2024434434
Jun 2024343431
Jul 2024585934
Aug 2024333024
Sep 2024363630
Oct 2024404021
Nov 2024454636
Dec 2024505126
Jan 2025424327
Feb 2025545440
Mar 2025616227
Apr 2025878747
May 2025393938
Jun 2025363718
Jul 2025110
Jan 2026110
Total413941722248